Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,359 result(s) found. Displaying page 2,202 of 2,218.
    «« First « Previous 2198  2199  2200  2201  2202  2203  2204  2205  2206  Next» Last»»
    EudraCT Number: 2018-004674-94 Sponsor Protocol Number: WI237607 Start Date*: 2019-04-05
    Sponsor Name:Riga Stradiņš University
    Full Title: Open-label Phase IV Study to Investigate Broad-and Cross-neutralizing Antibodies after Primary Vaccination with Two Different TBE Vaccines
    Medical condition: Active (prophylactic) immunization against tick-borne encephalitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10043847 Tick-borne viral encephalitis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-004686-41 Sponsor Protocol Number: IBA1160 Start Date*: 2020-12-02
    Sponsor Name:Helsinn Healthcare SA
    Full Title: MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
    Medical condition: Patients treated with IV moderately emetogenic chemotherapy and at high risk of chemotherapy induced nausea and vomiting (CINV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) CZ (Completed) DE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-017709-12 Sponsor Protocol Number: Y-55-52120-141 Start Date*: Information not available in EudraCT
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WIT...
    Medical condition: Lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10024132 Leg spasticity LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019102-17 Sponsor Protocol Number: Y-55-52120-147 Start Date*: Information not available in EudraCT
    Sponsor Name:Ipsen Pharma SAS
    Full Title: A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN C...
    Medical condition: Lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10024132 Leg spasticity LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-000356-17 Sponsor Protocol Number: 2 79 58035 700 Start Date*: Information not available in EudraCT
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: PHASE IIIB, INTERNATIONAL, SINGLE GROUP, OPEN STUDY TO DEFINE AN OPTIMAL MONITORING OF IGF-I IN CHILDREN TREATED WITH NUTROPINAQ USING A NOVEL CAPILLARY BLOOD COLLECTION METHOD
    Medical condition: growth failure associated with: - inadequate growth hormone secretion - Turner syndrome, confirmed by karyotype - chronic renal insufficiency up to renal transplantation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed) DK (Completed) AT (Completed) SE (Completed) FI (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-003591-13 Sponsor Protocol Number: V503-076 Start Date*: 2024-05-06
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Conco...
    Medical condition: Papilloma viral infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005823-35 Sponsor Protocol Number: 20201206 Start Date*: 2021-01-28
    Sponsor Name:Aarhus Universitet [...]
    1. Aarhus Universitet
    2. Aarhus Universitet
    3. Aarhus Universitet
    4. Aarhus Universitet
    Full Title: ILIT.FT – Dose finding for intralymphatic allergen immunotherapy in a randomized, parallel group, double blind placebo-controlled field trial
    Medical condition: Allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-002971-12 Sponsor Protocol Number: IMCgp100-201 Start Date*: 2016-05-26
    Sponsor Name:Immunocore Limited
    Full Title: A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compa...
    Medical condition: Advanced Malignant Cutaneous Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025655 Malignant melanoma of skin LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002013-20 Sponsor Protocol Number: ALKS4230-001 Start Date*: 2020-02-14
    Sponsor Name:Alkermes, Inc.
    Full Title: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2)
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Temporarily Halted) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-003662-21 Sponsor Protocol Number: ALKS4230-003 Start Date*: 2023-04-13
    Sponsor Name:Alkermes, Inc.
    Full Title: Clinical and Immunologic Activity of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumo...
    Medical condition: Patients with advanced solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007116 Cancer of skin (excl melanoma) LLT
    11.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038408 Renal cell carcinomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10086582 Microsatellite instability-high metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-004628-40 Sponsor Protocol Number: MRX-801 Start Date*: 2021-01-29
    Sponsor Name:Mirum Pharmaceuticals Inc
    Full Title: Open-Label, Phase 2 Study to Evaluate the Safety and Tolerability of Maralixibat in the Treatment of Infants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis ...
    Medical condition: Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10076033 Progressive familial intrahepatic cholestasis PT
    20.0 10010331 - Congenital, familial and genetic disorders 10053870 Alagille syndrome PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000807-99 Sponsor Protocol Number: 4SC-201-6-2015 Start Date*: 2016-09-15
    Sponsor Name:4SC AG
    Full Title: A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ...
    Medical condition: Advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) ES (Ongoing) AT (Completed) BE (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004842-27 Sponsor Protocol Number: Repha_1398 Start Date*: 2018-07-17
    Sponsor Name:Repha GmbH
    Full Title: Clinical Trial to investigate the efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in the prophylaxis of catheter associated urinary tract infections
    Medical condition: Prophylaxis of catheter-associated chronically inflammatory recurring urinary tract infections in adult patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10046544 Urinary infection LLT
    21.0 10021881 - Infections and infestations 10007810 Catheter related infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002822-10 Sponsor Protocol Number: PL101-HD301 Start Date*: 2020-12-11
    Sponsor Name:Prilenia Neurotherapeutics Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease
    Medical condition: Huntington Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) FR (Completed) CZ (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005097-25 Sponsor Protocol Number: KIDS-STEP Start Date*: Information not available in EudraCT
    Sponsor Name:Universitätskinderspital beider Basel (UKBB)
    Full Title: A randomised placebo-controlled multi-centre effectiveness trial of adjunct betamethasone therapy in hospitalised children with community acquired pneumonia (CAP)
    Medical condition: Children with community acquired pneumonia (CAP).
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004224-38 Sponsor Protocol Number: CNTO1275PUC3001 Start Date*: 2021-02-25
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) Outside EU/EEA BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005801-14 Sponsor Protocol Number: VAC31518COV3003 Start Date*: 2021-02-15
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults
    Medical condition: Healthy Volunteers (Prevention of SARS-CoV-2-mediated COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000007-21 Sponsor Protocol Number: 212620 Start Date*: 2021-08-16
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants wit...
    Medical condition: Moderate to severe Cholestatic pruritus with primary biliary cholangitis (PBC).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10064190 Cholestatic pruritus PT
    21.0 10019805 - Hepatobiliary disorders 10080429 Primary biliary cholangitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004163-12 Sponsor Protocol Number: 2020-012-GLOB1 Start Date*: 2021-11-04
    Sponsor Name:Hutchison MediPharma Limited
    Full Title: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003697-14 Sponsor Protocol Number: PsoPET2 Start Date*: 2017-12-18
    Sponsor Name:Aarhus University Hospital
    Full Title: A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with moderate-to-sever...
    Medical condition: Moderate-to-severe psoriasis. Vascular and systemic (splenic) inflammation in psoriasis subjects.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    20.0 100000004866 10003605 Atherosclerosis of aorta LLT
    20.0 100000004851 10041634 Spleen disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2198  2199  2200  2201  2202  2203  2204  2205  2206  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Sep 12 21:06:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA